ライフサイエンスコーパス: bucindolol

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 nt with the beta-blocker/sympatholytic agent bucindolol.

2 xperience greater sympatholytic effects from bucindolol.

3 rvival Trial (BEST; 1995-1999), of the 2707 (bucindolol=1353; placebo=1354) patients with heart failu

4 ease in plasma norepinephrine in response to bucindolol (-249+/-171 versus -35+/-277 pg/mL, P<0.05).

5 Bucindolol, a nonselective beta-receptor blocker, howeve

6 s and was predictive of outcomes in both the bucindolol and placebo treatment groups.

7 In contrast, bucindolol and xamoterol increased cAMP levels in a conc

8 In transfected cells, bucindolol antagonized agonist-stimulated cAMP, with a g

9 Gly-389 carriers had no clinical response to bucindolol compared with placebo.

10 Bucindolol exhibits approximately 60% of the beta-adrene

11 ihood-based method indicated that 18% of the bucindolol group but only 1% of the placebo group were a

12 owever, the Arg-389 homozygotes treated with bucindolol had an age-, sex-, and race-adjusted 38% redu

13 In BEST, a subset of patients treated with bucindolol had an increased risk of death as the result

14 Bucindolol has partial agonist properties in rat myocard

15 Bucindolol, however, significantly antagonized the respo

16 re assessed in a placebo-controlled trial of bucindolol in 1,040 HF patients.

17 d effectiveness of beta-blocker therapy with bucindolol in patients with HF enrolled in the Beta-Bloc

18 mias by the beta-blocker/sympatholytic agent bucindolol is influenced by genetic variation in adrener

19 tress echocardiography before treatment with bucindolol (n=41) or placebo (n=38).

20 l LVEF of 35% after 12 months, and effect of bucindolol on both outcomes were compared across HFREF s

21 d on one of three beta-blockers (carvedilol, bucindolol or metoprolol) and the dose was advanced to t

22 tes) who were randomized to the beta-blocker bucindolol or placebo in BEST and followed for mortality

23 Bucindolol prevents VT/VF in subjects with heart failure

24 ersely with change in LVEF after 3 months of bucindolol (r=-0.72, P<0.0001) and was the most signific

25 Bucindolol reduced VT/VF in beta(1)389 Arg homozygotes (

26 with heart failure, but one study assessing bucindolol reported a nonsignificant increase in mortali

27 ha(2c)322-325 polymorphism altered the VT/VF bucindolol response in beta1389 Gly carriers, with alpha

28 ZD 7114, xamoterol, and bucindolol significantly increased basal HR (DeltaHR: +1

29 nteraction between genotype and outcome with bucindolol that does not seem to occur with metoprolol o

30 To address this, we measured the ability of bucindolol to increase cAMP accumulation in human myocar

31 In the bucindolol-treated group but not in the placebo-treated

32 In the placebo-treated group but not in the bucindolol-treated group, marked norepinephrine increase

33 differ from a survival benefit reported for bucindolol-treated homozygous ADRB1 R389 individuals.

34 osis, improvement in LVEF, and the effect of bucindolol treatment differed significantly between subt

35 ociation class III/IV and LVEF < or =0.35 to bucindolol versus placebo.

36 The beta-blocker bucindolol was an inverse agonist in failing Arg, but no

37 In all genotypes bucindolol was associated with a lower incidence of VT/V

38 ol, alprenolol, bisoprolol, ICI 118,551, and bucindolol) was tested to prove the assay performance.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。